Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation

Journal of Clinical Oncology

Volumn 24, Issue 33, 2006, Pages 5207-5215

  Dekker, Allison ^a   Bulley, Sean ^a   Beyene, Joseph ^a   Dupuis, L Lee ^a   Doyle, John J ^a   Sung, Lillian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; ANTIINFECTIVE AGENT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BACTERIAL INFECTION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EUROPE; LENGTH OF STAY; METHODOLOGY; NEUTROPENIA; PRIMARY PREVENTION; RISK; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL; TIME; UNITED KINGDOM; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COST-BENEFIT ANALYSIS; DRUG COSTS; EUROPE; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GREAT BRITAIN; HUMANS; LENGTH OF STAY; NEUTROPENIA; ODDS RATIO; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNITED STATES;

EID: 34247344862     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.1663     Document Type: Article

References (59)

1. Lehrnbecher T, Welte K: Haematopoietic growth factors in children with neutropenia. Br J Haematol 116:28-56, 2002
2. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
3. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
4. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773-1778, 1991
5. Gulati SC, Bennett CL: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 116:177-182, 1992
6. Pettengell R, Gurney H, Radford JA, et al: Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial. Blood 80:1430-1436, 1992
7. Trillet-Lenoir V, Green J, Manegold C, et al: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319-324, 1993
8. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines: American Society of Clinical Oncology growth factors expert panel. J Clin Oncol 18:3558-3585, 2000
9. Smith TJC, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
10. Ringden O, Labopin M, Gorin NC, et al: Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 22:416-423, 2004
11. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 33:159-174, 1977
12. Van Tulder M, Furlan A, Bombardier C, et al: Updated method guidelines for systematic reviews in the Cochrane collaboration back review group. Spine 28:1290-1299, 2003
13. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
14. Sutton AJ, Duval SJ, Tweedie RL, et al: Empirical assessment of effect of publication bias on meta-analyses. BMJ 320:1574-1577, 2000
15. Davison AC, Hinkley DV: Bootstrap methods and their application. Cambridge, University Press, 1997
16. Efron B, Tsibirani R: Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:54-77, 1986
17. Asano S, Masaoka T, Takaku F: Beneficial effect of recombinant human glycosylated granulocyte colony-stimulating factor in marrow-transplanted patients: Results of multicenter phase II-III studies. Transplant Proc 23:1701-1703, 1991
18. Bishop MR, Tarantolo SR, Geller RB, et al: A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96:80-85, 2000
19. Dallorso S, Rondelli R, Messina C, et al: Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: Results of a prospective randomized trial. Haematologica 87:1274-1280, 2002
20. De Witte T, Gratwohl A, Van Der Lely N, et al: Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 79:1359-1365, 1992
21. De Witte T, Vreugdenhil G, Schattenberg A: Prolonged administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) after T-cell-depleted allogeneic bone marrow transplantation. Transplant Proc 25:57-60, 1993
22. Gisselbrecht C, Prentice HG, Bacigalupo A, et al: Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 343:696-700, 1994
23. Gonzalez-Vicent M, Madero L, Sevilla J, et al: A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. Bone Marrow Transplant 34:1077-1081, 2004
24. Gorin NC, Coiffier B, Hayat M, et al: Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: A double-blind placebo-controlled trial. Blood 80:1149-1157, 1992
25. Greenberg P, Advani R, Keating A, et al: GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow-Transplant 18:1057-1064, 1996
26. Hiraoka A, Masaoka T, Mizoguchi H, et al: Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: Double-blind placebo-controlled phase III clinical trial. J Clin Oncol 24:205-211, 1994
27. Hornedo J, Sola C, Solano C, et al: The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 29:737-743, 2002
28. Kawano Y, Takaue Y, Mimaya J, et al: Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: Results of a prospective randomized trial: The Japanese Cooperative Study Group of PBSCT. Blood 92:4040-4046, 1998
29. Khwaja A, Linch DC, Goldstone AH, et al: Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: A British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol 82:317-323, 1992
30. Klumpp TR, Mangan KF, Goldberg SL, et al: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial. J Clin Oncol 13:1323-1327, 1995
31. Lee SM, Radford JA, Dobson L, et al: Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: Clinical benefits at no extra cost. Br J Cancer 77:1294-1299, 1998
32. Legros M, Fleury J, Bay JO, et al: RhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: A phase III double-blind randomized trial. Bone Marrow Transplant 19:209-213, 1997
33. Linch DC, Scarffe H, Proctor S, et al: Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 11:307-311, 1993
34. Linch DC, Milligan DW, Winfield DA, et al: G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: Results of a randomized BNLI trial. Br J Haematol 99:933-938, 1997
35. Link H, Boogaerts MA, Carella AM, et al: A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 80:2188-2195, 1992
36. McQuaker IG, Hunter AE, Pacey S, et al: Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 15:451-457, 1997
37. Nemunaitis J, Rosenfeld CS, Ash R, et al: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 15:949-954, 1995
38. Ojeda E, Garcia-Bustos J, Aguado M, et al: A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 24:601-607, 1999
39. Piccirillo N, Sica S, Laurenti L, et al: Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 23:1245-1250, 1999
40. Powles R, Smith C, Milan S, et al: Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: Double-blind, placebo-controlled trial. Lancet 336:1417-1420, 1990
41. Przepiorka D, Smith TL, Folloder J, et al: Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 97:3405-3410, 2001
42. Schmitz N, Dreger P, Zander AR, et al: Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 15:261-266, 1995
43. Schmitz N, Ljungman P, Cordonnier C, et al: Lenograstim after autologous peripheral blood progenitor cell transplantation: Results of a double-blind, randomized trial. Bone Marrow Transplant 34:955-962, 2004
44. Spitzer G, Adkins DR, Spencer V, et al: Randomized study of growth factors post-peripheral-blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 12:661-670, 1994
45. Stahel RA, Jost LM, Cerny T, et al: Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 12:1931-1938, 1994
46. Trigg ME, Peters C, Zimmerman MB: Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation: A prospective, randomized, double-masked, placebo-controlled trial. Pediatr Transplant 4:123-131, 2000
47. Vannucchi AM, Bosi A, Ieri A, et al: Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: A randomized trial. Bone Marrow Transplant 17:527-531, 1996
48. Faber E, Pytlik R, Trneny M, et al: The individually deferred dosing of G-CSF after autologous stem cell transplantation in patients with malignant lymphoma: Results of multicentre randomised trial. Bone Marrow Transplant 35:S75-S76, 2005 (abstr)
49. Bennett CL, George SL, Vose JM, et al: Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: Implications for economic analyses of phase III clinical trials. Stem Cells 13:414-420, 1995
50. Brice P, Godin S, Libert O, et al: Effect of lenograstim on the cost of autologous bone marrow transplantation: A preliminary communication. Pharmacoeconomics 7:238-241, 1995
51. Luce BR, Singer JW, Weschler JM, et al: Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: An economic analysis of a randomised, double-blind, placebo-controlled trial. Pharmacoeconomics 6:42-48, 1994
52. Stinson TJ, Adams JR, Bishop MR, et al: Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant 26:663-666, 2000
53. Lyman GH, Kuderer NM, Djulbegovic B: Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. Am J Med 112:406-411, 2002
54. Bohlius J, Reiser M, Schwarzer G, et al: Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: A systematic review. Br J Haematol 122:413-423, 2003
55. Bohlius J, Reiser M, Schwarzer G, et al: Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev:CD003189, 2004
56. Sung L, Nathan PC, Lange B, et al: Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials. J Clin Oncol 22:3350-3356, 2004
57. Ho VT, Mirza NQ, Junco DD, et al: The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: A meta-analysis. Bone Marrow Transplant 32:771-775, 2003
58. Remberger M, Naseh N, Aschan J, et al: G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 32:217-223, 2003
59. Eapen M, Horowitz MM, Klein JP, et al: Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 22:4872-4880, 2004